Synribo (omacetaxine mepesuccinate ) for Injection 3.5 mg/vial
February 12, 2021
NINLARO (Ixazomib) Capsules
February 12, 2021


Facts of MabThera (rituximab.) 100 mg ?

  • Medicine Name: MabThera
  • Generic Name: rituximab
  • Approval Date: 2 June 2008
  • Company Name: Roche Pharma AG
  • Available as (Form & Strength): 100 mg Concentrated solution for infusion.

 Indications and Usage?

MabThera is indicated in adults for the following indications:

  • MabThera is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy.
  • MabThera in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including MabThera or patients refractory to previous MabThera plus chemotherapy.
  • MabThera, in combination with glucocorticoids, is indicated for the induction of remission in adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).

Leave a Reply

Your email address will not be published. Required fields are marked *